A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs CPI-100 (Primary)
- Indications Tumours
- Focus Adverse reactions; First in man
- Sponsors Coordination Pharmaceuticals
- 31 Dec 2018 Status changed from not yet recruiting to recruiting.
- 18 Dec 2018 Status changed from planning to not yet recruiting.
- 11 Oct 2018 New trial record